Swine Mycoplasma Infections: Diagnosis and Management

Mycoplasma infections in swine present as two primary clinical syndromes: respiratory disease caused by Mycoplasma hyopneumoniae and arthritis caused by Mycoplasma hyosynoviae. These bacterial pathogens lack cell walls, which influences diagnostic approaches, treatment options, and control strategies. Swine veterinarians and herd health managers must distinguish between these species and their clinical presentations to implement effective management protocols. This article provides diagnostic protocols, antimicrobial therapy considerations, and vaccination strategies for both M. hyopneumoniae and M. hyosynoviae infections based on available evidence from the World Organisation for Animal Health (WOAH), the Merck Veterinary Manual (Merck Veterinary Manual), and peer-reviewed literature.

At a Glance

Clinical Syndromes and Pathogen Characteristics

Mycoplasma hyopneumoniae Respiratory Infection

Mycoplasma hyopneumoniae is the primary bacterial agent associated with enzootic pneumonia in swine. The organism colonizes the ciliated epithelium of the respiratory tract, leading to ciliostasis, epithelial damage, and impaired mucociliary clearance. This damage predisposes pigs to secondary bacterial infections, particularly Pasteurella multocida, Actinobacillus pleuropneumoniae, and Streptococcus suis. Clinical signs include a dry, nonproductive cough, reduced growth rates, and decreased feed efficiency. The Merck Veterinary Manual (Merck Veterinary Manual) describes M. hyopneumoniae as a key component of the porcine respiratory disease complex (PRDC). Infection typically occurs through direct contact with respiratory secretions from infected pigs. Transmission can occur from sows to piglets during lactation and between pen mates during the nursery and finishing phases.

Mycoplasma hyosynoviae Arthritis

Mycoplasma hyosynoviae causes arthritis primarily in grower and finisher pigs, typically between 10 and 20 weeks of age. The organism colonizes the tonsils and upper respiratory tract of pigs and can become systemic, localizing in joints. A case report published in Porcine Health Management examined lameness in fattening pigs and identified M. hyosynoviae, osteochondropathy, and reduced dietary phosphorus level as three influencing factors (Lameness in fattening pigs - Mycoplasma hyosynoviae, osteochondropathy and reduced dietary phosphorus level as three influencing factors: a case report, Porcine Health Management, 2020). Clinical signs include acute lameness, joint swelling, reluctance to move, and reduced weight gain. Affected pigs may show stiffness, particularly in the stifle, hock, and elbow joints. The condition can lead to increased culling rates and welfare concerns. Research published in the Journal of Veterinary Medicine described M. hyosynoviae arthritis in grower-finisher pigs, noting that lameness can appear suddenly and affect multiple pigs within a group (Mycoplasma hyosynoviae arthritis in grower-finisher pigs, Journal of Veterinary Medicine, 2001).

Mycoplasma hyorhinis Considerations

Mycoplasma hyorhinis is another species that can cause polyserositis and arthritis in pigs, typically in nursery to early finishing stages. The organism can infect serosal surfaces, leading to pericarditis, pleuritis, and peritonitis, as well as joint inflammation. Research on vaccination against M. hyorhinis has been conducted, with studies examining protection in commercial pigs through immunization with inactivated vaccines prepared with homologous or heterologous strains (Protection against Mycoplasma hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains, Vaccine, 2024). Another study evaluated the efficacy of an inactivated M. hyorhinis vaccine in pigs (Efficacy of an inactivated Mycoplasma hyorhinis vaccine in pigs, Vaccine, 2018). While M. hyorhinis is less commonly discussed than M. hyopneumoniae and M. hyosynoviae, it should be considered in differential diagnoses for arthritis and polyserositis in younger pigs.

Diagnostic Approaches

Clinical Observation and History

The first step in diagnosing mycoplasma infections is careful clinical observation. For respiratory cases, record the prevalence and character of coughing, respiratory rates, and growth performance across groups. For lameness cases, document the number of affected pigs, the joints involved, the severity of lameness, and the age distribution. A study from Southwestern Norway examined M. hyosynoviae-associated arthritis in finisher pigs showing signs of lameness, highlighting the importance of clinical surveillance in detecting outbreaks (Mycoplasma hyosynoviae-associated arthritis in finisher pigs showing signs of lameness in Southwestern Norway, Acta Veterinaria Scandinavica, 2026). Herd history, including vaccination protocols, previous disease outbreaks, and management changes, provides essential context.

Sample Collection and Handling

Proper sample collection is critical for accurate diagnosis. For M. hyopneumoniae, collect lung tissue from acutely affected pigs at necropsy, bronchoalveolar lavage fluid from live pigs, or deep nasal swabs. For M. hyosynoviae, collect joint fluid and synovial membrane samples from affected joints, and tonsil swabs for carrier detection. A study published in Veterinary Microbiology described the use of a novel serum ELISA method and the tonsil-carrier state for evaluation of M. hyosynoviae distributions in pig herds with or without clinical arthritis (Use of a novel serum ELISA method and the tonsil-carrier state for evaluation of Mycoplasma hyosynoviae distributions in pig herds with or without clinical arthritis, Veterinary Microbiology, 2005). Samples should be placed in appropriate transport media and kept cool during transport to the laboratory. Mycoplasmas are fragile organisms, and delays in processing can reduce isolation success.

Laboratory Diagnostic Methods

Polymerase chain reaction (PCR) is the most sensitive and specific method for detecting mycoplasma DNA in clinical samples. PCR can differentiate between M. hyopneumoniae, M. hyosynoviae, and M. hyorhinis. Serology using enzyme-linked immunosorbent assay (ELISA) can detect antibodies against M. hyopneumoniae and M. hyosynoviae, indicating exposure. Culture of mycoplasmas requires specialized media and is less commonly used in routine diagnostics due to the slow growth of these organisms. Histopathology of lung tissue can reveal characteristic lesions of enzootic pneumonia, including peribronchiolar lymphoid hyperplasia and bronchopneumonia. For arthritis cases, examination of joint fluid and synovial membrane can support the diagnosis. A review published in the Journal of Swine Health and Production outlined critical points for diagnosis of mycoplasma-associated arthritis (Mycoplasma-associated arthritis: Critical points for diagnosis, Journal of Swine Health and Production, 2012).

Differential Diagnoses

For respiratory disease, differential diagnoses include other agents of the porcine respiratory disease complex such as Actinobacillus pleuropneumoniae, Pasteurella multocida, Streptococcus suis, Haemophilus parasuis, and viral pathogens including porcine reproductive and respiratory syndrome virus (PRRSV), swine influenza virus, and porcine circovirus type 2 (PCV2). For arthritis, differential diagnoses include Streptococcus suis, Haemophilus parasuis, Erysipelothrix rhusiopathiae, Trueperella pyogenes, and osteochondropathy. The case report from Porcine Health Management emphasized that osteochondropathy and reduced dietary phosphorus level can contribute to lameness alongside M. hyosynoviae infection (Lameness in fattening pigs - Mycoplasma hyosynoviae, osteochondropathy and reduced dietary phosphorus level as three influencing factors: a case report, Porcine Health Management, 2020). A thorough diagnostic workup should include testing for these differentials.

Treatment Protocols

Antimicrobial Therapy Considerations

Mycoplasmas lack cell walls, making them inherently resistant to beta-lactam antimicrobials such as penicillins and cephalosporins. Effective antimicrobial classes include tetracyclines, macrolides, lincosamides, pleuromutilins, and fluoroquinolones. The choice of antimicrobial should be based on sensitivity testing when possible, regulatory approval for swine, and withdrawal period requirements. A study published in The Veterinary Record examined the use of tiamulin in a herd of pigs seriously affected with M. hyosynoviae arthritis (Use of tiamulin in a herd of pigs seriously affected with Mycoplasma hyosynoviae arthritis, The Veterinary Record, 1984). Tiamulin is a pleuromutilin antimicrobial with activity against mycoplasmas. Treatment protocols should be developed in consultation with a veterinarian and must comply with local regulations regarding antimicrobial use in food animals.

Treatment Administration Routes

For respiratory disease, antimicrobials can be administered through feed or water for group treatment, or by injection for individual pigs. For arthritis cases, individual injection is often necessary because affected pigs may not eat or drink adequately. The duration of treatment should be sufficient to resolve clinical signs, typically 5 to 7 days for acute cases. Severely affected pigs may require longer treatment courses. Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used to reduce inflammation and pain in arthritic pigs, improving welfare and recovery.

Treatment Failure and Resistance

Treatment failure can occur due to inadequate dosage, insufficient duration of treatment, antimicrobial resistance, or misdiagnosis. If clinical signs do not improve within 48 to 72 hours of initiating treatment, reevaluate the diagnosis and consider sensitivity testing. Antimicrobial resistance in mycoplasmas has been reported, particularly to tetracyclines and macrolides. The World Organisation for Animal Health (WOAH) provides guidance on prudent use of antimicrobials in animals to minimize the development of resistance. The Animal Health and Welfare division of WOAH (Animal Health and Welfare) addresses antimicrobial resistance as a key priority.

Vaccination Strategies

Mycoplasma hyopneumoniae Vaccination

Commercial vaccines for M. hyopneumoniae are widely available and are typically administered to piglets between 1 and 3 weeks of age, with a booster dose given 2 to 4 weeks later. Some vaccines are also approved for use in sows to provide passive immunity to piglets through colostrum. Vaccination reduces the severity of lung lesions, improves growth rates, and reduces the prevalence of secondary infections. However, vaccination does not prevent colonization or eliminate the organism from the herd. The Merck Veterinary Manual (Merck Veterinary Manual) notes that vaccination is a key component of control programs for enzootic pneumonia. Herd-specific vaccination protocols should be developed based on the timing of exposure, management system, and concurrent disease challenges.

Mycoplasma hyosynoviae Vaccination

No commercial vaccines for M. hyosynoviae are widely available at this time. Research has explored the transfer of maternal immunity to piglets and its role in early protection against M. hyosynoviae infection (Transfer of maternal immunity to piglets is involved in early protection against Mycoplasma hyosynoviae infection, Veterinary Immunology and Immunopathology, 2017). This study indicated that maternal antibodies can provide some protection to piglets, but the duration and level of protection are limited. Control of M. hyosynoviae relies on management practices, antimicrobial treatment of affected pigs, and reduction of stress factors that predispose to disease.

Mycoplasma hyorhinis Vaccination

Research on M. hyorhinis vaccination has shown promise. A study published in Vaccine examined protection against M. hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains (Protection against Mycoplasma hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains, Vaccine, 2024). Another study evaluated the efficacy of an inactivated M. hyorhinis vaccine in pigs (Efficacy of an inactivated Mycoplasma hyorhinis vaccine in pigs, Vaccine, 2018). These studies suggest that vaccination may be a viable control strategy for M. hyorhinis, but commercial availability may vary by region.

Herd Management and Biosecurity

Reducing Transmission

Mycoplasmas are transmitted through direct contact with infected pigs and through aerosolized respiratory secretions. For M. hyopneumoniae, transmission occurs primarily through nose-to-nose contact and aerosol over short distances. For M. hyosynoviae, transmission occurs through contact with infected tonsil secretions. Biosecurity measures to reduce transmission include all-in/all-out production systems, adequate ventilation, reduced stocking density, and separation of age groups. The World Organisation for Animal Health (WOAH) provides standards for biosecurity in swine production.

Stress Reduction

Stress factors such as overcrowding, poor ventilation, temperature fluctuations, mixing of pigs from different sources, and concurrent infections can increase the severity of mycoplasma infections. Management practices that minimize stress include providing adequate space per pig, maintaining optimal environmental conditions, implementing gradual diet changes, and using proper handling techniques. For M. hyosynoviae, reducing stress during the grower and finisher phases may help prevent clinical outbreaks.

Nutritional Considerations

The case report from Porcine Health Management identified reduced dietary phosphorus level as a contributing factor to lameness in fattening pigs alongside M. hyosynoviae infection and osteochondropathy (Lameness in fattening pigs - Mycoplasma hyosynoviae, osteochondropathy and reduced dietary phosphorus level as three influencing factors: a case report, Porcine Health Management, 2020). This finding highlights the importance of balanced nutrition, particularly calcium and phosphorus levels, in maintaining joint health and reducing the impact of mycoplasma arthritis. Consult with a swine nutritionist to ensure diets meet the requirements for each production stage.

Records and Measurements

Clinical Records

Maintain records of clinical signs observed, including the date of onset, number of pigs affected, severity of signs, and response to treatment. For respiratory cases, record coughing scores, respiratory rates, and mortality. For lameness cases, record the number of lame pigs, joints affected, and culling rates. These records help identify patterns and evaluate the effectiveness of interventions.

Diagnostic Records

Document all diagnostic samples submitted, including sample types, collection dates, laboratory results, and interpretation. Keep records of PCR, serology, and culture results for each submission. These records support herd health monitoring and help track changes in pathogen prevalence over time.

Treatment Records

Record all antimicrobial treatments administered, including product name, dose, route, duration, and withdrawal period. Document the number of pigs treated, the response to treatment, and any adverse reactions. These records are essential for regulatory compliance and for evaluating treatment protocols.

Vaccination Records

Maintain records of all vaccinations administered, including product name, batch number, dose, route, date, and age of pigs vaccinated. Document any adverse reactions or lack of expected efficacy. These records support herd health planning and troubleshooting.

Common Failure Patterns

Incomplete Diagnosis

A common failure pattern is treating for mycoplasma infection without confirming the diagnosis through laboratory testing. Clinical signs of respiratory disease and lameness can have multiple causes, and treatment may be ineffective if the wrong pathogen is targeted. Always submit appropriate samples for laboratory confirmation before initiating treatment, particularly in outbreaks affecting multiple pigs.

Inadequate Treatment Duration

Mycoplasma infections often require longer treatment durations than bacterial infections with cell-walled organisms. Stopping treatment too early can lead to relapse and may contribute to antimicrobial resistance. Follow veterinary recommendations for treatment duration and monitor pigs for recurrence of clinical signs.

Poor Biosecurity

Introducing new pigs into a herd without adequate quarantine and testing can introduce mycoplasma strains to which the herd has no immunity. Maintain quarantine protocols for incoming stock and consider testing for M. hyopneumoniae and M. hyosynoviae before introduction.

Concurrent Infections

Mycoplasma infections often occur alongside other pathogens. For respiratory disease, M. hyopneumoniae frequently coexists with PRRSV, PCV2, and secondary bacterial infections. For arthritis, M. hyosynoviae can occur with Streptococcus suis or Haemophilus parasuis. A comprehensive diagnostic workup should include testing for common coinfections.

Welfare and Safety Context

Animal Welfare Implications

Mycoplasma infections have significant welfare implications. Respiratory disease causes respiratory distress, reduced appetite, and lethargy. Arthritis causes pain, lameness, and difficulty moving, which can prevent pigs from accessing feed and water. The World Organisation for Animal Health (WOAH) includes animal welfare as a core component of its standards, and the Animal Health and Welfare division (Animal Health and Welfare) addresses welfare in livestock production. Prompt diagnosis and treatment of mycoplasma infections are essential for maintaining acceptable welfare standards.

Human Safety Considerations

Mycoplasmas that infect swine are not considered zoonotic, meaning they do not cause disease in humans. However, the antimicrobials used to treat mycoplasma infections require careful handling and adherence to withdrawal periods to ensure food safety. Always follow label instructions and regulatory requirements for antimicrobial use in food animals.

Regulatory Compliance

Antimicrobial use in swine is regulated to ensure food safety and minimize the development of antimicrobial resistance. The World Organisation for Animal Health (WOAH) provides international standards for antimicrobial use in animals. Veterinarians and producers must comply with local regulations regarding prescription, dispensing, and record-keeping for antimicrobials. Withdrawal periods must be observed to prevent violative residues in meat.

Professional Escalation Criteria

Urgent Veterinary Consultation

Seek immediate veterinary consultation if:

• Multiple pigs develop acute lameness or respiratory distress within a short period
• Mortality rates increase suddenly
• Pigs are unable to stand or access feed and water
• Treatment with an appropriate antimicrobial does not produce improvement within 48 hours
• You suspect a notifiable disease that could be confused with mycoplasma infection

Routine Veterinary Consultation

Schedule a veterinary consultation if:

• Chronic cough or lameness persists in a group of pigs
• Growth rates or feed efficiency are below targets
• Vaccination protocols need review or adjustment
• You are considering changes to antimicrobial treatment protocols
• You need assistance with diagnostic sample collection and interpretation

Diagnostic Laboratory Referral

Refer samples to a diagnostic laboratory when:

• Initial treatment has failed and you need sensitivity testing
• You need to differentiate between mycoplasma species
• You suspect coinfections with other pathogens
• You are investigating a herd-level problem and need comprehensive testing

Practical Decision Framework for Mycoplasma Infection Management in Swine Herds

Managing mycoplasma infections in swine requires structured decision-making that accounts for herd-specific factors, diagnostic capabilities, and treatment options. A systematic framework helps veterinarians and producers move from clinical observation to effective intervention while avoiding common pitfalls that lead to treatment failure or disease recurrence. This section presents a practical decision framework that integrates diagnostic thresholds, treatment selection criteria, and monitoring protocols for both M. hyopneumoniae and M. hyosynoviae infections.

Clinical Threshold Assessment

The first step in the decision framework involves establishing clinical thresholds that trigger diagnostic investigation. For respiratory disease potentially caused by M. hyopneumoniae, initiate diagnostic testing when coughing prevalence exceeds 10 percent in any production group, when average daily gain falls below target by more than 5 percent over a two-week period, or when mortality from respiratory causes exceeds 2 percent in nursery or finishing pigs. The Merck Veterinary Manual (Merck Veterinary Manual) notes that M. hyopneumoniae is a key component of the porcine respiratory disease complex, and clinical thresholds should account for concurrent infections that may amplify disease severity.

For lameness potentially caused by M. hyosynoviae, initiate diagnostic testing when lameness prevalence exceeds 3 percent in grower or finisher pigs, when culling due to lameness exceeds 1 percent per month, or when multiple pigs within a two-week age range develop acute lameness simultaneously. A study published in Acta Veterinaria Scandinavica examined M. hyosynoviae-associated arthritis in finisher pigs showing signs of lameness in Southwestern Norway, emphasizing that acute onset lameness in multiple pigs warrants immediate investigation (Mycoplasma hyosynoviae-associated arthritis in finisher pigs showing signs of lameness in Southwestern Norway, Acta Veterinaria Scandinavica, 2026). These thresholds provide objective criteria for initiating diagnostic workup instead of relying solely on subjective clinical impression.

Diagnostic Decision Tree

Once clinical thresholds are met, follow a structured diagnostic decision tree that guides sample selection and laboratory testing based on the predominant clinical syndrome. For respiratory cases, collect samples from three to five acutely affected pigs that have not received antimicrobial treatment within the previous 48 hours. Submit lung tissue from euthanized pigs with gross lesions consistent with enzootic pneumonia, bronchoalveolar lavage fluid from live pigs under sedation, or deep nasal swabs from pigs with active coughing. Request PCR testing that differentiates M. hyopneumoniae from other respiratory pathogens including Actinobacillus pleuropneumoniae, Pasteurella multocida, and Streptococcus suis.

For lameness cases, collect joint fluid and synovial membrane samples from three to five pigs with acute lameness that have not received antimicrobial treatment within the previous 48 hours. Select joints with visible swelling or heat, typically the stifle, hock, or elbow. Also collect tonsil swabs from affected and unaffected pen mates to assess carrier status. A study published in Veterinary Microbiology described the use of a novel serum ELISA method and the tonsil-carrier state for evaluation of M. hyosynoviae distributions in pig herds with or without clinical arthritis (Use of a novel serum ELISA method and the tonsil-carrier state for evaluation of Mycoplasma hyosynoviae distributions in pig herds with or without clinical arthritis, Veterinary Microbiology, 2005). Request PCR testing that differentiates M. hyosynoviae from M. hyorhinis, Streptococcus suis, Haemophilus parasuis, and Erysipelothrix rhusiopathiae.

When PCR results are positive for a mycoplasma species, consider follow-up serology to assess population-level exposure and immunity. For M. hyopneumoniae, collect serum samples from 10 to 20 pigs per production group across multiple age ranges to determine the timing of seroconversion. For M. hyosynoviae, serology can help differentiate between recent infection and chronic carrier status. The Journal of Swine Health and Production outlined critical points for diagnosis of mycoplasma-associated arthritis, including the importance of combining PCR and serology results for accurate interpretation (Mycoplasma-associated arthritis: Critical points for diagnosis, Journal of Swine Health and Production, 2012).

Treatment Selection Criteria

After confirming mycoplasma infection through laboratory testing, select antimicrobial therapy based on species identification, clinical severity, and herd-specific factors. For M. hyopneumoniae respiratory disease in groups where more than 10 percent of pigs show clinical signs, consider group treatment through feed or water using tetracyclines, macrolides, or pleuromutilins. For individual pigs with severe respiratory distress, injectable antimicrobials from the same classes provide more rapid therapeutic concentrations. Treatment duration should extend for 7 to 10 days for group medication and 5 to 7 days for individual injections, with clinical improvement expected within 48 to 72 hours.

For M. hyosynoviae arthritis, individual injectable therapy is typically necessary because affected pigs may not consume adequate feed or water for group treatment to be effective. A study published in The Veterinary Record examined the use of tiamulin in a herd of pigs seriously affected with M. hyosynoviae arthritis, demonstrating that pleuromutilins can be effective when administered appropriately (Use of tiamulin in a herd of pigs seriously affected with Mycoplasma hyosynoviae arthritis, The Veterinary Record, 1984). Injectable tetracyclines, macrolides, or pleuromutilins are appropriate choices. Administer treatment for 5 to 7 days, and consider adding nonsteroidal anti-inflammatory drugs to reduce joint inflammation and pain. Pigs that cannot stand or access feed and water should be euthanized on welfare grounds instead of subjected to prolonged treatment with poor prognosis.

When selecting antimicrobials, consider regulatory approval for swine, withdrawal period requirements, and the potential for antimicrobial resistance. The World Organisation for Animal Health (WOAH) provides guidance on prudent use of antimicrobials in animals to minimize the development of resistance. The Animal Health and Welfare division of WOAH (Animal Health and Welfare) addresses antimicrobial resistance as a key priority. Document all treatment decisions, including product name, dose, route, duration, and withdrawal period, for regulatory compliance and future reference.

Response Evaluation Protocol

Evaluate treatment response at 48 to 72 hours after initiating therapy using objective criteria. For respiratory cases, assess coughing scores, respiratory rates, and appetite. For lameness cases, assess the number of pigs able to stand and move freely, the degree of joint swelling, and the proportion of pigs returning to feed and water access. Document the response as improved, unchanged, or worsened.

If clinical signs have improved, continue the prescribed treatment course to completion. If clinical signs are unchanged or worsened, reevaluate the diagnosis through additional laboratory testing, including antimicrobial sensitivity testing if possible. Consider the possibility of concurrent infections that may require additional or different therapy. For respiratory cases, evaluate for PRRSV, PCV2, or secondary bacterial infections. For lameness cases, evaluate for Streptococcus suis, Haemophilus parasuis, or osteochondropathy. A case report published in Porcine Health Management examined lameness in fattening pigs and identified M. hyosynoviae, osteochondropathy, and reduced dietary phosphorus level as three influencing factors, highlighting the importance of considering noninfectious causes when treatment fails (Lameness in fattening pigs - Mycoplasma hyosynoviae, osteochondropathy and reduced dietary phosphorus level as three influencing factors: a case report, Porcine Health Management, 2020).

If treatment failure is confirmed despite appropriate antimicrobial selection and administration, submit samples for culture and sensitivity testing. Mycoplasma culture requires specialized media and is less commonly available than PCR, but sensitivity testing can guide selection of alternative antimicrobials. Consider switching to a different antimicrobial class to address potential resistance. For example, if a tetracycline was used initially and failed, consider a macrolide or pleuromutilin.

Herd-Level Intervention Planning

When mycoplasma infection is confirmed at the herd level, develop a comprehensive intervention plan that addresses immediate treatment, medium-term control, and long-term prevention. For M. hyopneumoniae, the intervention plan should include vaccination of piglets at 1 to 3 weeks of age with a booster 2 to 4 weeks later, all-in/all-out production flow, adequate ventilation, and reduced stocking density. The Merck Veterinary Manual (Merck Veterinary Manual) notes that vaccination is a key component of control programs for enzootic pneumonia. Consider vaccinating sows to provide passive immunity to piglets through colostrum.

For M. hyosynoviae, no commercial vaccines are widely available, so the intervention plan must focus on management practices and antimicrobial treatment of affected pigs. Research has explored the transfer of maternal immunity to piglets and its role in early protection against M. hyosynoviae infection (Transfer of maternal immunity to piglets is involved in early protection against Mycoplasma hyosynoviae infection, Veterinary Immunology and Immunopathology, 2017). While maternal antibodies can provide some protection, the duration and level of protection are limited. Reduce stress factors that predispose to clinical disease, including overcrowding, poor ventilation, temperature fluctuations, and mixing of pigs from different sources. Ensure balanced nutrition, particularly calcium and phosphorus levels, as the case report from Porcine Health Management identified reduced dietary phosphorus level as a contributing factor to lameness (Lameness in fattening pigs - Mycoplasma hyosynoviae, osteochondropathy and reduced dietary phosphorus level as three influencing factors: a case report, Porcine Health Management, 2020).

For herds with recurrent M. hyosynoviae outbreaks, consider strategic antimicrobial medication of high-risk groups during the period of peak susceptibility, typically 10 to 16 weeks of age. This approach should be used judiciously and in consultation with a veterinarian to minimize the development of antimicrobial resistance. Document the timing and duration of strategic medication and evaluate its effectiveness through monitoring of lameness prevalence and treatment response.

Monitoring and Surveillance System

Implement a monitoring and surveillance system that tracks key indicators of mycoplasma infection and treatment effectiveness. For respiratory disease, monitor weekly coughing scores, monthly average daily gain, and mortality rates. Calculate the percentage of pigs treated for respiratory disease and the percentage that require retreatment or are euthanized due to poor response. For lameness, monitor weekly lameness prevalence, monthly culling rates due to lameness, and the number of pigs treated for arthritis. Calculate the percentage of treated pigs that return to normal function within 7 days.

Conduct periodic serological monitoring to assess population-level exposure and immunity. For M. hyopneumoniae, collect serum samples from 10 to 20 pigs per production group every 6 to 12 months to track seroconversion patterns. For M. hyosynoviae, serological monitoring can help identify the timing of exposure and assess the effectiveness of management interventions. A study published in Veterinary Microbiology described the use of a novel serum ELISA method for evaluation of M. hyosynoviae distributions in pig herds (Use of a novel serum ELISA method and the tonsil-carrier state for evaluation of Mycoplasma hyosynoviae distributions in pig herds with or without clinical arthritis, Veterinary Microbiology, 2005). Compare serological results with clinical observations to validate the monitoring system.

Maintain records of all diagnostic submissions, treatment protocols, and outcomes. Review these records quarterly to identify trends and adjust intervention plans as needed. Share records with your veterinarian during routine herd health visits to facilitate collaborative decision-making.

Escalation Criteria for Professional Consultation

Establish clear escalation criteria that trigger veterinary consultation when the decision framework indicates the need for expert input. Escalate to veterinary consultation when:

• Clinical signs do not improve within 72 hours of initiating appropriate antimicrobial therapy
• Lameness prevalence exceeds 5 percent despite treatment and management interventions
• Mortality from respiratory disease exceeds 3 percent in any production group
• Multiple treatment failures occur within a single production group
• Antimicrobial sensitivity testing is needed to guide treatment selection
• Herd-level intervention planning requires expert input
• You suspect a notifiable disease that could be confused with mycoplasma infection

The World Organisation for Animal Health (WOAH) provides standards for disease reporting and veterinary oversight in swine production. Prompt veterinary consultation ensures that treatment decisions are based on current evidence and regulatory requirements.

Common Decision Errors

Several common errors undermine the effectiveness of the decision framework. The first error is initiating treatment without laboratory confirmation of mycoplasma infection. Clinical signs of respiratory disease and lameness have multiple causes, and treatment directed at the wrong pathogen wastes resources and delays effective therapy. Always submit appropriate samples for laboratory confirmation before initiating treatment, particularly in outbreaks affecting multiple pigs.

The second error is using inadequate antimicrobial doses or treatment durations. Mycoplasma infections often require higher doses and longer treatment durations than bacterial infections with cell-walled organisms. Follow veterinary recommendations for dosing and duration, and do not stop treatment early even if clinical signs appear to resolve. Stopping treatment too early can lead to relapse and may contribute to antimicrobial resistance.

The third error is neglecting concurrent infections and predisposing factors. Mycoplasma infections frequently occur alongside other pathogens or management deficiencies. For respiratory disease, M. hyopneumoniae often coexists with PRRSV, PCV2, and secondary bacterial infections. For arthritis, M. hyosynoviae can occur with Streptococcus suis, Haemophilus parasuis, or osteochondropathy. A comprehensive diagnostic workup should include testing for common coinfections and evaluation of management factors such as nutrition, ventilation, and stocking density.

The fourth error is failing to monitor treatment response objectively. Subjective assessment of clinical improvement can be misleading, particularly when multiple pigs are affected. Use objective criteria such as coughing scores, lameness scores, and growth rates to evaluate treatment effectiveness. Document these measurements in herd records for future reference.

The fifth error is implementing the same intervention repeatedly without evaluating its effectiveness. If a treatment protocol or management intervention does not produce the expected results, investigate the reasons for failure and adjust the approach accordingly. This may involve changing antimicrobials, modifying vaccination protocols, or addressing underlying management deficiencies.

Integration with Herd Health Records

Integrate the decision framework with existing herd health records to create a comprehensive system for managing mycoplasma infections. Record clinical thresholds that triggered diagnostic investigation, diagnostic results, treatment protocols, response evaluations, and intervention plans. Use these records to identify patterns over time, such as seasonal increases in lameness or respiratory disease, and to evaluate the effectiveness of control measures.

Share records with your veterinarian during routine herd health visits to facilitate collaborative decision-making. The World Organisation for Animal Health (WOAH) emphasizes the importance of record-keeping for disease surveillance and antimicrobial stewardship. The Animal Health and Welfare division of WOAH (Animal Health and Welfare) provides guidance on record-keeping practices for livestock producers.

Review the decision framework annually and update it based on new evidence, changes in herd status, and evolving regulatory requirements. The framework should be a living document that adapts to the specific needs of your herd and the latest scientific understanding of mycoplasma infections in swine.

Frequently Asked Questions

What is the difference between Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae?

Mycoplasma hyopneumoniae primarily causes respiratory disease (enzootic pneumonia) in pigs, characterized by coughing, reduced growth, and predisposition to secondary bacterial infections. Mycoplasma hyosynoviae primarily causes arthritis and lameness in grower and finisher pigs, typically affecting the stifle, hock, and elbow joints. Both are mycoplasma species but target different organ systems.

How is mycoplasma infection diagnosed in pigs?

Diagnosis is based on clinical signs, laboratory testing, and postmortem examination. PCR testing of appropriate samples (lung tissue, bronchoalveolar lavage fluid, joint fluid, tonsil swabs) is the most sensitive and specific method. Serology using ELISA can detect antibodies indicating exposure. Culture requires specialized media and is less commonly used. Histopathology of lung or joint tissue can support the diagnosis.

What antimicrobials are effective against mycoplasma in swine?

Effective antimicrobial classes include tetracyclines, macrolides, lincosamides, pleuromutilins, and fluoroquinolones. Mycoplasmas lack cell walls, so beta-lactam antimicrobials such as penicillins and cephalosporins are not effective. The choice of antimicrobial should be based on sensitivity testing when possible, regulatory approval, and withdrawal period requirements. Tiamulin, a pleuromutilin, has been studied for use in M. hyosynoviae arthritis.

Can mycoplasma infections be prevented through vaccination?

Commercial vaccines for M. hyopneumoniae are widely available and are a key component of control programs for enzootic pneumonia. No commercial vaccines for M. hyosynoviae are widely available at this time. Research on M. hyorhinis vaccination has shown promise, but commercial availability may vary by region. Vaccination should be combined with good management practices for optimal control.

What management practices reduce the risk of mycoplasma outbreaks?

Management practices that reduce risk include all-in/all-out production systems, adequate ventilation, reduced stocking density, separation of age groups, stress reduction, balanced nutrition (particularly calcium and phosphorus levels), and biosecurity measures such as quarantine of incoming stock. Minimizing concurrent infections through vaccination and good husbandry also helps.

How long does treatment for mycoplasma arthritis typically take?

Treatment duration depends on the severity of the infection and the response to therapy. Acute cases typically require 5 to 7 days of antimicrobial treatment. Severely affected pigs may require longer courses. Nonsteroidal anti-inflammatory drugs can be used to reduce inflammation and pain. If clinical signs do not improve within 48 to 72 hours, reevaluate the diagnosis and consider sensitivity testing.

Is mycoplasma infection in pigs a risk to human health?

Mycoplasmas that infect swine are not considered zoonotic and do not cause disease in humans. However, the antimicrobials used to treat mycoplasma infections require careful handling and adherence to withdrawal periods to ensure food safety. Always follow label instructions and regulatory requirements for antimicrobial use in food animals.

What should I do if treatment for mycoplasma infection fails?

If treatment fails, first confirm the diagnosis through laboratory testing. Consider antimicrobial sensitivity testing to identify effective drugs. Evaluate the dosage, route, and duration of treatment. Check for concurrent infections that may be contributing to clinical signs. Review management practices for factors that may predispose pigs to infection. Consult with a veterinarian to develop a revised treatment and control plan.

Related Veterinary Guides

• Pig Lameness Monitoring And Flooring Management
• Swine Respiratory Disease Observation And Diagnostics
• Manure Management For Pig Farms
• Pig Farm Odor Management And Neighbor Relations
• Swarm Prevention And Management

References and Further Reading

• World Organisation for Animal Health
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Lameness in fattening pigs - Mycoplasma hyosynoviae, osteochondropathy and reduced dietary phosphorus level as three influencing factors: a case report.. Porcine health management, 2020.
• Mycoplasma hyosynoviae arthritis in grower-finisher pigs.. Journal of veterinary medicine. A, Physiology, pathology, clinical medicine, 2001.
• Mycoplasma hyosynoviae-associated arthritis in finisher pigs showing signs of lameness in Southwestern Norway.. Acta veterinaria Scandinavica, 2026.
• Use of tiamulin in a herd of pigs seriously affected with Mycoplasma hyosynoviae arthritis.. The Veterinary record, 1984.
• Protection against Mycoplasma hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains.. Vaccine, 2024.
• Efficacy of an inactivated Mycoplasma hyorhinis vaccine in pigs.. Vaccine, 2018.
• Mycoplasma Hyosynoviae in Joints with Arthritis in Abattoir Baconers. Acta Veterinaria Scandinavica, 1992.
• Use of a novel serum ELISA method and the tonsil-carrier state for evaluation of Mycoplasma hyosynoviae distributions in pig herds with or without clinical arthritis. Veterinary Microbiology, 2005.
• Transfer of maternal immunity to piglets is involved in early protection against Mycoplasma hyosynoviae infection. Veterinary Immunology and Immunopathology, 2017.
• Mycoplasma-associated arthritis: Critical points for diagnosis. Journal of Swine Health and Production, 2012.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.